Editorial: Immune Checkpoint Molecules and Cancer Immunotherapy

Editorial: Immune Checkpoint Molecules and Cancer Immunotherapy

Bibliographic Details
Main Authors:	Alexandr V. Bazhin, Amedeo Amedei, Svetlana Karakhanova
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2018-12-01
Series:	Frontiers in Immunology
Subjects:	immune checkpoint molecules cancer immunotherapy CTLA-4 (CD152) PD-1 (CD279) PDL1
Online Access:	https://www.frontiersin.org/article/10.3389/fimmu.2018.02878/full

Similar Items

Immune Checkpoint Inhibition for Pancreatic Cancer
by: Seyed Aria Nejadghaderi, et al.
Published: (2023-05-01)

Pivotal antitumor role of the immune checkpoint molecule B7-H1 in pancreatic cancer
by: Alexandr V. Bazhin, et al.
Published: (2022-12-01)

Metabolic Checkpoints: Novel Avenues for Immunotherapy of Cancer
by: Ivan Shevchenko, et al.
Published: (2018-08-01)

Interferon-α Up-Regulates the Expression of PD-L1 Molecules on Immune Cells Through STAT3 and p38 Signaling
by: Alexandr V. Bazhin, et al.
Published: (2018-09-01)

Find the Flame: Predictive Biomarkers for Immunotherapy in Melanoma
by: Mattia Garutti, et al.
Published: (2021-04-01)

CD279 mediates the homeostasis and survival of regulatory T cells by enhancing T cell and macrophage interactions
by: Yang Liu, et al.
Published: (2020-06-01)

Efficacy and safety of immune checkpoint inhibitors for patients with prostate cancer: a systematic review and meta-analysis
by: Maryam Noori, et al.
Published: (2023-10-01)

Cure the Incurable? Recent Breakthroughs in Immune Checkpoint Blockade for Hepatocellular Carcinoma
by: Pei-Yi Chu, et al.
Published: (2021-10-01)

Immune Checkpoint Inhibition for Triple-Negative Breast Cancer: Current Landscape and Future Perspectives
by: Huimei Yi, et al.
Published: (2021-05-01)

Comparative Transcriptomics of Immune Checkpoint Inhibitor Myocarditis Identifies Guanylate Binding Protein 5 and 6 Dysregulation
by: Daniel Finke, et al.
Published: (2021-05-01)

Differential expression of the costimulatory molecules CD86, CD28, CD152 and PD-1 correlates with the host-parasite outcome in leprosy
by: Maria de Lourdes Palermo, et al.
Published: (2012-12-01)

Recent Advances in Immunotherapy in Metastatic NSCLC.
by: Pranshu Bansal, et al.
Published: (2016-11-01)

CD96 as a Potential Immune Regulator in Cancers
by: Shikai Feng, et al.
Published: (2023-01-01)

Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons
by: Adel Naimi, et al.
Published: (2022-04-01)

Immune Checkpoint Inhibitors: Ctla-4 and Pd-1/Pd-l1 in Immunotherapy
by: Kübra KAHVECİ, et al.
Published: (2019-12-01)

Immune Checkpoint in Glioblastoma: Promising and Challenging
by: Jing Huang, et al.
Published: (2017-05-01)

CD163-positive tumor-associated macrophages and CD8-positive cytotoxic lymphocytes are powerful diagnostic markers for the therapeutic stratification of osteosarcoma patients: An immunohistochemical analysis of the biopsies fromthe French OS2006 phase 3 trial
by: Anne Gomez-Brouchet, et al.
Published: (2017-09-01)

Cardiotoxicity of FDA-approved immune checkpoint inhibitors: A rare but serious adverse event
by: Abdulrazzak Zarifa, et al.
Published: (2018-10-01)

On the Other Side: Manipulating the Immune Checkpoint Landscape of Dendritic Cells to Enhance Cancer Immunotherapy
by: Benjamin Y. Kong, et al.
Published: (2019-02-01)

Idiopathic CD4 T Cell Lymphocytopenia: A Case of Overexpression of PD-1/PDL-1 and CTLA-4
by: Gaurav Kumar, et al.
Published: (2021-01-01)

Immune Checkpoint Inhibitors in Cancer Therapy
by: Yavar Shiravand, et al.
Published: (2022-04-01)

Immune Checkpoint Pathway Expression in Lymphocyte Subpopulations in Patients with Common Variable Immunodeficiency and Chronic Lymphocytic Leukemia
by: Paulina Mertowska, et al.
Published: (2023-10-01)

The Role of Immune Checkpoint Inhibitors in Cancer Therapy
by: Ahmed M. Basudan
Published: (2022-12-01)

Immune Checkpoint Molecules—Inherited Variations as Markers for Cancer Risk
by: Marta Wagner, et al.
Published: (2021-01-01)

Combining vaccines and immune checkpoint inhibitors to prime, expand, and facilitate effective tumor immunotherapy
by: Julie M. Collins, et al.
Published: (2018-08-01)

Progress Toward Identifying Exact Proxies for Predicting Response to Immunotherapies
by: Aleksandra Filipovic, et al.
Published: (2020-03-01)

Combinatorial blockade for cancer immunotherapy: targeting emerging immune checkpoint receptors
by: Dia Roy, et al.
Published: (2023-10-01)

Adenosinergic axis and immune checkpoint combination therapy in tumor: A new perspective for immunotherapy strategy
by: Zhaoyun Liu, et al.
Published: (2022-09-01)

MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: targeting PD-1/PD-L1 and CTLA-4 pathways
by: Arefeh Zabeti Touchaei, et al.
Published: (2024-03-01)

Immunotherapy of Ovarian Cancer with Particular Emphasis on the PD-1/PDL-1 as Target Points
by: Janina Świderska, et al.
Published: (2021-12-01)

The clinical promise of immunotherapy in triple-negative breast cancer
by: Vikas P, et al.
Published: (2018-12-01)

The Use of Phytochemicals to Improve the Efficacy of Immune Checkpoint Inhibitors: Opportunities and Challenges
by: Deniz Can Guven, et al.
Published: (2022-10-01)

Immune checkpoint blockade therapy: The 2014 Tang prize in biopharmaceutical science
by: Ya-Shan Chen, et al.
Published: (2015-02-01)

IMMUNE CHECKPOINT INHIBITION AND AUTOIMMUNITY: RHEUMATOLOGICAL PROBLEMS
by: E. L. Nasonov
Published: (2018-03-01)

Checkpoint Inhibitors and the Gut
by: Tuan Tran, et al.
Published: (2022-02-01)

Is There Still Room for Cancer Vaccines at the Era of Checkpoint Inhibitors
by: Soumaya Karaki, et al.
Published: (2016-11-01)

Pancreatic Ductal Adenocarcinoma and Immune Checkpoint Inhibitors: The Gray Curtain of Immunotherapy and Spikes of Lights
by: Rita Balsano, et al.
Published: (2023-03-01)

Targeting Immune Checkpoint Molecules to Eliminate Latent HIV
by: Zoe Boyer, et al.
Published: (2018-10-01)

Deregulated Expression of Immune Checkpoints on Circulating CD4 T Cells May Complicate Clinical Outcome and Response to Treatment with Checkpoint Inhibitors in Multiple Myeloma Patients
by: Anna Kulikowska de Nałęcz, et al.
Published: (2021-08-01)

Immune checkpoint inhibitors and prostate cancer: a new frontier?
by: Alessandra Modena, et al.
Published: (2016-04-01)